Less than one quarter of pathology labs have adopted whole-slide imaging so far, but pathologists and companies in the space are optimistic of continued growth.

The national contract covers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.

The tool uses two blood-based biomarkers and up to five clinical features to generate a risk score for prostate cancer aggressiveness.

The change applies to qualitative and quantitative hepatitis B virus antigen, antibody, and nucleic acid assays that are used to detect acute and chronic infections.

The agreement includes $650 million of 4.35 percent senior notes, $500 million of 4.55 percent senior notes, and $850 million of 4.8 percent senior notes.

The Baltimore-based subsidiary of Japan's Sysmex said that the test is used to identify genetic mutations that are relevant for the treatment of various cancer types.

The letter encourages drug developers to "further study and use" αSyn-SAA testing for selecting patients for clinical trials for Parkinson's and related diseases.

Quest will become the exclusive independent national laboratory provider of clinical lab and anatomic pathology services for Sentara members in Florida and Virginia.

The drop represents a return to a more normal pace of openings post-pandemic but likely also reflects the reimbursement and regulatory challenges facing the industry.